|
Pre- and post-chemotherapy LMR
|
No. of patients
|
Progression-free survival (months)
|
Overall survival (months)
|
|---|
|
Median (95% CI)
|
HR (95% CI)
|
P value
|
Median (95% CI)
|
HR (95% CI)
|
P value*
|
|---|
|
Low–low
|
87
|
5.8 (5.1–6.5)
|
1
| |
13.0 (10.3–15.7)
|
1
| |
|
Low–high
|
129
|
8.4 (7.7–9.1)
|
0.524 (0.391–0.702)
|
<0.001
|
17.8 (16.9–18.7)
|
0.522 (0.371–0.771)
|
<0.001
|
|
High–low
|
151
|
8.2 (7.8–8.6)
|
0.733 (0.636–0.846)
|
<0.001
|
17.0 (15.6–18.4)
|
0.837 (0.699–1.003)
|
0.053
|
|
High–high
|
121
|
10.6 (9.8–11.4)
|
0.631 (0.566–0.702)
|
<0.001
|
22.2 (21.0–23.4)
|
0.636 (0.562–0.719)
|
<0.001
|
- Abbreviations as in Tables 1 and 2
- *Tested by COX proportional hazards model in which the reference is the low–low group, and adjusted with the ECOG performance status, number of metastatic sites, and differentiation
